Trial Profile
Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Post-traumatic headache; Traumatic brain injuries
- Focus Therapeutic Use
- 16 Jun 2022 Status changed from not yet recruiting to recruiting.
- 16 Jun 2022 Planned End Date changed from 15 Dec 2027 to 19 May 2027.
- 16 Jun 2022 Planned primary completion date changed from 15 Dec 2026 to 19 May 2026.